title: Effect of tamoxifen alone and in combination with RU 486 on the endometrium in the mid-luteal phase.
abstract: The effects of RU 486 combined with tamoxifen and tamoxifen alone on hormonal parameters and endometrial development at the time of implantation were studied. Measurements of cytosolic oestrogen and progesterone receptors in endometrium and placental protein 14 (PP14) in plasma were also included. Three dosage schedules were used: single oral dose of 40 mg tamoxifen alone and in combination with 200 mg RU 486, and 40 mg tamoxifen for three consecutive days starting on the first day after the luteinizing hormone (LH) surge. The combined treatment prolonged the luteal phase (P < 0.05) and increased the plasma levels of progesterone. A single dose of tamoxifen did not affect the bleeding pattern and plasma hormone levels, but raised plasma oestradiol and LH with the 3-day treatment. The endometrium was retarded after the combined and the 3-day treatment with tamoxifen. Concentrations of cytosolic progesterone receptors were higher after the combined therapy, but were unaffected after tamoxifen only. PP14 levels were higher (P < 0.05) after repeated tamoxifen doses than in controls, but were lower with combined treatment. Progesterone and oestrogen are evidently necessary for endometrial maturation during the secretory phase of the menstrual cycle. PP14 levels in plasma cannot be used for clinical assessments of endometrial function because high levels coincide with disturbed endometrial development.
authors: Department of Obstetrics and Gynaecology, Karolinska Hospital, Stockholm, Sweden.
authors: M L
authors: ML
authors: Swahn
authors: M
authors: M
authors: Bygdeman
authors: M
authors: M
authors: Seppälä
authors: E
authors: E
authors: Johannisson
authors: S
authors: S
authors: Cekan
mesh_terms: D010064:Embryo Implantation / Q000502:physiology; D004717:Endometrium / Q000187:drug effects*; D004967:Estrogens / Q000378:metabolism; D005260:Female; D000071816:Glycodelin; D006023:Glycoproteins; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects*; D007986:Luteinizing Hormone / Q000378:metabolism; D015735:Mifepristone / Q000494:pharmacology*; D011257:Pregnancy Proteins / Q000097:blood*; D011374:Progesterone / Q000378:metabolism; D011987:Receptors, Steroid / Q000187:drug effects / Q000378:metabolism; D012636:Secretory Rate / Q000502:physiology; D013629:Tamoxifen / Q000494:pharmacology*
chemical_list: D004967:Estrogens; D000071816:Glycodelin; D006023:Glycoproteins; D006728:Hormones; C045246:PAEP protein, human; D011257:Pregnancy Proteins; D011987:Receptors, Steroid; D013629:Tamoxifen; D015735:Mifepristone; D011374:Progesterone; D007986:Luteinizing Hormone